Article Information
PMID
Published By
Print ISSN
0250-7005
Online ISSN
1791-7530
History
- Received July 5, 2023
- Revision received July 27, 2023
- Accepted July 28, 2023
- Published online September 29, 2023.
Copyright & Usage
Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Author Information
- FUMIHIKO URABE1,#,
- DAIGO KOBAYASHI1,#,
- KOSUKE IWATANI1,
- YU IMAI1,
- HAJIME ONUMA1,
- KOICHI AIKAWA1,
- TAKAFUMI YANAGISAWA1,
- KOJIRO TASHIRO1,
- HIROSHI SASAKI1,
- JUN MIKI1,2,
- KENTA MIKI1 and
- TAKAHIRO KIMURA1⇑
- 1Department of Urology, The Jikei University School of Medicine, Tokyo, Japan;
- 2Department of Urology, The Jikei University School of Medicine, Kashiwa Hospital, Chiba, Japan
- Correspondence to: Takahiro Kimura, Department of Urology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, Japan. Tel: +81 0334331111, Fax: +81 0354001387, e-mail: tkimura{at}jikei.ac.jp
↵# These Authors contributed equally to this study.
Statistics from Altmetric.com
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- Risk Factors and Clinical Significance of Grade >=3 Neutropenia During the First Cycle of Cabazitaxel Therapy With Primary Pegfilgrastim Prophylaxis in Metastatic Castration-resistant Prostate Cancer
- Patients Diagnosed With Metastatic Castration-sensitive Prostate Cancer and High Serum Lactate Dehydrogenase Levels Did Not Receive an Adequate Dose of Cabazitaxel
- Impact of Novel Agents on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer